Syprine Related Published Studies
Well-designed clinical trials related to Syprine (Trientine)
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. [2006.04]
Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy. [2004.06]
Well-designed clinical trials possibly related to Syprine (Trientine)
Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults. [2009.08]
Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. [2009.05.01]
A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. [2009.04]
Other research related to Syprine (Trientine)
Evaluation of Cuprimine(R) and Syprine(R) for decorporation of radioisotopes of cesium, cobalt, iridium and strontium. [2011.08]
Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po. [2010.03]
Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. [2009.09]
Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. [2009.08]
The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. [2009]
Combined effects of treatment with trientine, a copper-chelating agent, and x-irradiation on tumor growth in transplantation model of a murine fibrosarcoma. [2007.10]
Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment. [2007.05]
Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease. [2007.02]
Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice. [2005.07]
[Wilson's disease with severe neurological manifestations: response to trientine plus zinc therapy] [2004.05]
Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. [2003.12]
The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. [2003.02]
Effects of trientine, a metal chelator, on defective endothelium-dependent relaxation in the mesenteric vasculature of diabetic rats. [2002.10]
The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. [2001.12.15]
Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. [2001.04]
Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation? [2001.02]
Effects of interactions between drugs on the renal excretion of trientine in rats--acetazolamide and furosemide increase trientine excretion. [1999.12]
[Case of superficial hemosiderosis of the central nervous system treated with trientine] [1998.04]
The mechanism of excretion of trientine from the rat kidney: trientine is not recognized by the H+/organic cation transporter. [1997.04]
[Disposition behavior and absorption mechanism of trientine, an orphan drug for Wilson's disease] [1996.03]
Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). [1995.09]
[Wilson disease: a new case treated with trientine] [1995.01]
[A study of trientine therapy in Wilson's disease with neurological symptoms] [1993.09]
Evaluation of the efficacy of d-penicillamine and trientine as copper chelators using an in vitro technique involving ovine red blood cells. [1992.09]
Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations. [1992]
Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine). [1990.01]
Other possibly related research studies
Anticopper therapy against cancer and diseases of inflammation and fibrosis. [2005.08.15]
[Acute liver failure and hemolysis in a 16-year-old woman. First manifestation of Wilson's disease] [2005.09.15]
Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. [2005]
Hydroxyl stereochemistry and amine number within poly(glycoamidoamine)s affect intracellular DNA delivery. [2005.03.09]
Wilson disease in septuagenarian siblings: Raising the bar for diagnosis. [2005.03]
Wilson's disease: clinical, genetic and pharmacological findings. [2005.01]
Wilson's disease. [1998.02]
Pathophysiology and clinical features of Wilson disease. [2004.12]
[Wilson's disease and its pharmacological treatment] [2004.11]
Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. [2004.08.24]
[Pathogenesis and treatment of Wilson's disease] [2003]
Results of treatment of Wilson's disease--own observations. [2003.08]
[Wilson disease in 2003] [2003.12.14]
Review article: diagnosis and current therapy of Wilson's disease. [2004.01.15]
Current and future therapy in haemochromatosis and Wilson's disease. [2003.12]
[Electrophysiological impairment profile of patients with Wilson's disease] [2003.10]
Wilson disease. [2003.09]
[Peripheral haemosiderosis of the central nervous system] [2003.07]
Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. [2003.01]
[The role of copper in tumor angiogenesis--clinical implications] [2002]
[Superficial siderosis of the central nervous system: a case report] [2002.12]
Wilson's disease. [2002.09]
Diagnosis and treatment of Wilson's disease. [2002.07]
Diagnosis and treatment of Wilson's disease. [2002.02]
Personality traits in treated Wilson's disease determined by means of the Karolinska Scales of Personality (KSP). [2001.09]
Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease. [2001.03]
Haemolytic onset of Wilson disease in a patient with homozygous truncation of ATP7B at Arg1319. [2001.07]
Iatrogenic copper deficiency associated with long-term copper chelation for treatment of copper storage disease in a Bedlington Terrier. [2001.05.15]
[The role of zinc in the initial treatment of Wilson's disease in children] [2000.03]
Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant. [2000.04]
Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. [2000.02]
Recognition, diagnosis, and management of Wilson's disease. [2000.01]
Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. [1999.09]
Treatment and management of Wilson's disease. [1999.08]
[Therapy of Wilson disease] [1999.04]
Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease. [1998.12]
Subacute and chronic toxicity studies of triethylenetetramine dihydrochloride (TJA-250) by oral administration to F-344 rats. [1998.10]
Treatment of Wilson's disease with zinc: XV long-term follow-up studies. [1998.10]
Zinc acetate treatment in Wilson's disease. [1998.01]
Pharmacokinetics and material balance studies of diethylenetriamine trihydrochloride in the Fischer 344 rat following oral, endotracheal or intravenous dosing. [1997.11]
[Wilson's disease] [1997.01]
Nerve function and regeneration in diabetic and galactosaemic rats: antioxidant and metal chelator effects. [1996.10.24]
Acquired sideroblastic anaemia induced by a copper-chelating agent. [1996.07]
Subchronic toxicity of triethylenetetramine dihydrochloride in B6C3F1 mice and F344 rats. [1996.02]
Wilson disease: genetic basis of copper toxicity and natural history. [1996.02]
Reversibility of cerebral ventricular enlargement in anorexia nervosa, demonstrated by quantitative magnetic resonance imaging. [1996.02]
Wilson's disease in pregnancy. [1995.09]
Practical recommendations and new therapies for Wilson's disease. [1995.08]
Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. [1995.08]
[Wilson's disease--evolutive panorama of diagnosis and treatment in the last forty years] [1995.03]
[Wilson's disease: physiopathology, therapeutic approach and case report] [1994.12]
Superficial hemosiderosis of the central nervous system. [1994.09]
Current status of orphan disease drug development. [1994.04]
The cupruretic effect of two chelators following copper loading in sheep. [1993.10]
Duration and dose-related effects of an orally administered, partially lipophilic polyaminocarboxylic acid on the decorporation of plutonium and americium. [1993.10]
Chelation treatment of neurological Wilson's disease. [1993.03]
Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. [1993.02]
Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. [1993.01]
Low copper and brain abnormalities in fetus from triethylene tetramine dihydrochloride-treated pregnant mouse. [1992.12]
Decorporation of plutonium by oral administration of a partially lipophilic polyaminocarboxylic acid. [1992.08]
[Wilson's disease with primary CNS manifestation--current status in diagnosis and therapy] [1992.06]
Wilson's disease: current status. [1992.06]
[Wilson's disease] [1992.05]
Kayser-Fleischer rings in a patient with basal cell carcinoma: fortuitous diagnosis of presymptomatic Wilson's disease. [1992.02]
Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease. [1991.06]
Triethylene-tetramine (trien) therapy for Wilson's disease. [1991.05]
Prognosis of Wilsonian chronic active hepatitis. [1991.03]
[Intestinal absorption and urinary excretion of triethylenetetramine for Wilson's disease in rat] [1990.10]
Liver copper concentration in Wilson's disease: effect of treatment with 'anti-copper' agents. [1990.07]
Involvement of corticospinal tract in Wilson's disease. A study of three cases with transcranial stimulation. [1990]
|